Rencofilstat
Based on 1 publication(s) in Google Scholar
Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 90.29%
- CAS No.: 1383420-08-3
- 화학식: C67H122N12O13
- 분자량:1303.76
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Rencofilstat
MoreAll Cyclophilin Isoforms
More
Biological Activity
|
Cyclophilin A 2.5 nM (IC50) |
Cyclophilin B 3.1 nM (IC50) |
Cyclophilin D 2.8 nM (IC50) |
Cyclophilin G 7.3 nM (IC50) |
Rencofilstat (1 nM-1 µM, 3 days) inhibits NFAT and IL-2 signaling pathways in Juakat cell, exhibits immunosuppressive activity[1].
Rencofilstat (0.6-80 μM, 3 days) inhibits the cell viability of Jurkat E6.1 lymphocyte cell, HepaRG hepatocyte cell, primary renal epithelial cell, primary dermal fibroblasts, primary bronchial smooth muscle cell, and primary umbilical vein endothelial cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat E6.1, HepaRG, primary renal epithelial cell, primary dermal fibroblasts, primary bronchial smooth muscle cell, and primary umbilical vein endothelial cell
-
Concentration:0.6-80 μM
-
Incubation Time:3 days
-
Result:Inhibited cell viability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse nonalcoholic steatohepatitis (NASH) model[1]
-
Dosage:50 mg/kg
-
Administration:po, daily for 8 weeks
-
Result:Decreased liver fibrosis, reduced the number and size of liver tumors.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1383420-08-3
-
Appearance Solid
-
분자량 1303.76
-
화학식 C67H122N12O13
-
Color White to off-white
-
SMILES
O[C@@H]([C@](C(N[C@H](C(N([C@@H](C(N([C@H](C(N[C@H](C(N([C@H]1CC(C)C)C)=O)C(C)C)=O)CC(C)C)C)=O)C)C)=O)CC)=O)([H])N(C([C@@H](N(C([C@@H](N(C([C@@H](N(C([C@H](NC([C@@H](NC1=O)C)=O)C)=O)C)CC(C)C)=O)C)CC(C)C)=O)C)C(C)C)=O)C)[C@H](C)CCCCCCNC(C)=O
-
Synonyms
CRV431
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
A preclinical candidate of cyclophilin D inhibition improves alcohol-associated liver injury. [Abstract]2026 Mar 17;7(3):102654. PMID: 41850244
용액&용해도
DMSO : 50 mg/mL (38.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.7670 mL | 3.8351 mL | 7.6701 mL | 19.1753 mL |
| 5 mM | 0.1534 mL | 0.7670 mL | 1.5340 mL | 3.8351 mL | |
| 10 mM | 0.0767 mL | 0.3835 mL | 0.7670 mL | 1.9175 mL | |
| 15 mM | 0.0511 mL | 0.2557 mL | 0.5113 mL | 1.2784 mL | |
| 20 mM | 0.0384 mL | 0.1918 mL | 0.3835 mL | 0.9588 mL | |
| 25 mM | 0.0307 mL | 0.1534 mL | 0.3068 mL | 0.7670 mL | |
| 30 mM | 0.0256 mL | 0.1278 mL | 0.2557 mL | 0.6392 mL |
Rencofilstat Related Classifications
HY-135644 Related Classifications
Powered by Bioz